Bayer Pulls Remaining Trasylol From U.S. Market

Law360, New York (May 15, 2008, 12:00 AM EDT) -- Bayer AG has yanked the leftover stock of its blood-clotting drug Trasylol from the U.S. market amid increasing fears that the drug may cause kidney failure and increase the risk of death.

Bayer HealthCare Pharmaceuticals Inc. had opted to remove the remaining stock from warehouses and hospitals as lawsuits over the medication trickle into the courts, the U.S. Food and Drug Administration announced Wednesday.

“The FDA will work with Bayer to ensure a smooth and complete process,” the agency said.

At the FDA's urging, Bayer suspended...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.